Reference: Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)
The SARS-CoV-2 virus spreading across the world has led to surges of COVID-19 illness, hospitalizations, and death. The complex and multifaceted pathophysiology of life-threatening COVID-19 illness including viral mediated organ damage, cytokine storm, and thrombosis warrants early interventions to address all components of the devastating illness. In countries where therapeutic nihilism is prevalent, patients endure escalating symptoms and without early treatment can succumb to delayed in-hospital care and death.
Tags: Ambulatory treatment, Anti-inflammatory, Anticoagulant, antiplatelet agent, Antiviral, corticosteroid, COVID-19, SARS-CoV-2
Reference: Pathophysiological basis and rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) infection
Approximately 9 months of the severe acute respiratory syndrome coronavius-2 (SARS-CoV-2 [COVID-19]) spreading across the globe has led to widespread COVID-19 acute hospitalizations and death. The rapidity and highly communicable nature of the SARS-CoV-2 outbreak has hampered the design and execution of definitive randomized, controlled trials of therapy outside of the clinic or hospital.
Categories: I-CARE Early Covid
Tags: Ambulatory treatment, Anti-inflammatory, Anticoagulant, Antiviral, COVID-19, Critical care, Epidemiology, SARS-CoV-2